NEW YORK (GenomeWeb) – Editas Medicine announced it has signed a three-year collaboration agreement with Cystic Fibrosis Foundation Therapeutics.

Under the terms of the agreement, CFFT will pay Editas up to $5 million to support discovery and development of CRISPR/Cas9-based therapies for cystic fibrosis. CFFT will also provide its network of experts to Editas. On its end, Editas has agreed to explore common mutations driving the disease as well as those not currently addressed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.